Our study demonstrates that low-molecular-weight heparin (LMWH) prophylaxis confers significant benefit primarily in high-risk subgroups of women with inherited thrombophilia (IT)—specifically those with a history of severe pregnancy complications or carriers of highly thrombogenic mutations such as factor V Leiden (FVL). This evidence concerns the gene F5 and Rare hereditary thrombophilia.